Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01698554 · ClinicalTrials.gov registry record · Phase 3
Bimatoprost in the Treatment of Eyelash Hypotrichosis
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 464
- Enrollment target
NCT01698554 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 464 participants.
The verdict
NCT01698554, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 464 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSE®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).
Interventions
- DRUG bimatoprost formulation A solution
- DRUG bimatoprost solution 0.03 %
- DRUG vehicle of bimatoprost formulation A solution
- DRUG vehicle of bimatoprost solution 0.03 %
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01698554
The ClinicalTrials.gov registry entry for NCT01698554 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 464 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which bimatoprost formulation A solution is the first listed.
NCT01698554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01698554 about?
NCT01698554 is a clinical study titled "Bimatoprost in the Treatment of Eyelash Hypotrichosis". This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSE®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).
What is the current status of trial NCT01698554?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 464 participants. The study started on 2012-11. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01698554?
The interventions under investigation include: bimatoprost formulation A solution (DRUG), bimatoprost solution 0.03 % (DRUG), vehicle of bimatoprost formulation A solution (DRUG), vehicle of bimatoprost solution 0.03 % (DRUG).
Who is sponsoring clinical trial NCT01698554?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.